Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06391034 · ClinicalTrials.gov registry record · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Robert Bok, MD, PhD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 161
- Enrollment target
- 1
- Study location
NCT06391034 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by Robert Bok, MD, PhD. The registered enrollment target is 161 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06391034, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by Robert Bok, MD, PhD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 161 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy for prostate cancer.
Conditions Studied
Interventions
- DRUG hyperpolarized pyruvate +/-urea (13C/15N)
- RADIATION Non-investigational External beam radiotherapy (EBRT)
- PROCEDURE Radiotherapy (RT)
- PROCEDURE Multi-parametric magnetic resonance imaging (mpMRI)
- BIOLOGICAL Non-interventional hormone therapy
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2024-09-24 |
| Est. Completion | 2032-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06391034
The ClinicalTrials.gov registry entry for NCT06391034 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (74% lower). The listed sponsor is Robert Bok, MD, PhD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which hyperpolarized pyruvate +/-urea (13C/15N) is the first listed.
NCT06391034 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06391034 about?
NCT06391034 is a clinical study titled "Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer". This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy for prostate cancer.
What is the current status of trial NCT06391034?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 161 participants. The study started on 2024-09-24. Estimated completion is 2032-10-31.
What conditions does trial NCT06391034 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06391034?
The interventions under investigation include: hyperpolarized pyruvate +/-urea (13C/15N) (DRUG), Non-investigational External beam radiotherapy (EBRT) (RADIATION), Radiotherapy (RT) (PROCEDURE), Multi-parametric magnetic resonance imaging (mpMRI) (PROCEDURE), Non-interventional hormone therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT06391034?
This trial is sponsored by Robert Bok, MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06391034 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.